Under construction – not a live service
Sign in
Taking people in ChinaNo phase

Improving Prostate Cancer Biopsy Targeting With MRI and Real-Time Metabolic Feedback

Builds a system to guide where biopsy samples are taken in prostate cancer.

Plain-language title generated from the registry record
Registry title: Development of an Intraoperative Adaptive Biopsy System for Prostate Cancer: Integrating Imaging Navigation With Metabolic Feedback for Dynamic Decision-Making

Key facts

Where
Shanghai, ChinaSee the 4 sites

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men aged 55 or older who need a prostate biopsy and have recent PSA blood test results and a multiparametric MRI scan.

Age
55 years or older
Sex
Men only
Biomarker or test result
Total PSA and free PSA levels and a multiparametric MRI (mpMRI) result must be available within 1 month before the biopsy.

Main reasons for not taking part

  • A cancer diagnosis other than prostatic acinar adenocarcinoma
  • Another cancer that could affect imaging results, such as rectal, bladder or testicular cancer
  • Cachexia (severe wasting) or organ function decompensation

Read by machine on 13 November 2026.

Where in China

  • Minhang Hospital, Fudan UniversityShanghai, ChinaContact: Minhang Hospital, Fudan UniversityTaking people
  • Shanghai Geriatric Medical CenterShanghai, ChinaContact: Shanghai Geriatric Medical CenterTaking people
  • Xuhui Hospital, Fudan UniversityShanghai, ChinaContact: Xuhui Hospital, Fudan UniversityTaking people
  • Zhongshan Hospital,Fudan UniversityShanghai, ChinaContact: Zhongshan Hospital, Fudan UniversityTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Shanghai Zhongshan Hospital
Trial code
NCT07856017
Record updated
2 October 2026
Original description
Development of an Intelligent System Integrating Preoperative Imaging and Real-Time Intraoperative Metabolic Feedback to Dynamically Optimize Biopsy core Placement for Individualized Precision Sampling.Read full original descriptionShow less

An MRI-Based Diagnostic Model for Prostate Cancer Localization: An Exploratory Study Integrating Radiomics and the Metabolic Microenvironment

Development of an Intelligent System Integrating Preoperative Imaging and Real-Time Intraoperative Metabolic Feedback to Dynamically Optimize Biopsy core Placement for Individualized Precision Sampling.

Inclusion: Age ≥55 years; Indication for prostate biopsy; Availability of total prostate-specific antigen (tPSA), free PSA (fPSA) levels, and multiparametric MRI (mpMRI) results within 1 month prior to biopsy.

Exclusion: Concomitant malignant tumors potentially affecting imaging findings (e.g., rectal, bladder, or testicular cancer); Pathological diagnosis of malignancies other than prostatic acinar adenocarcinoma; Cachexia or organ function decompensation.

ClinicalTrials.gov NCT07856017